About
Blood Products
Areas of Focus
Categories
Biologics & BiopharmaceuticalJapan
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
4
As Collaborator
1
Total Enrollment
344
By Phase
PHASE3: 4PHASE2/PHASE3: 1
By Status
COMPLETED: 5
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Today
Hover over trial bars to see details
Recent Trials
NCT04182373Collaborator
KW-3357 Study in Patients With Early Onset Severe Preeclampsia
PHASE3Completed
181 participants
Started: Nov 19, 2019 · Completed: Jun 16, 2023
NCT02342184Lead Sponsor
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
PHASE3Completed
21 participants
Started: Aug 31, 2014 · Completed: Sep 30, 2015
NCT02184741Lead Sponsor
A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent Miscarriage
PHASE3Completed
99 participants
Started: Jun 3, 2014 · Completed: Sep 30, 2020
NCT02032095Lead Sponsor
The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.
PHASE2/PHASE3Completed
17 participants
Started: Nov 30, 2013 · Completed: Sep 30, 2015
NCT00335985Lead Sponsor
Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)
PHASE3Completed
26 participants
Started: Jun 30, 2006 · Completed: Mar 31, 2009
Locations (1)
Headquarters
Tokyo, Japan
Map
Loading map...